These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 9210715)

  • 61. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
    Steuber T; Vickers AJ; Serio AM; Vaisanen V; Haese A; Pettersson K; Eastham JA; Scardino PT; Huland H; Lilja H
    Clin Chem; 2007 Feb; 53(2):233-40. PubMed ID: 17185368
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Assessment of optimal target genes for detecting micrometastases in pelvic lymph nodes in patients with prostate cancer undergoing radical prostatectomy by real-time reverse transcriptase-polymerase chain reaction.
    Kusuda Y; Miyake H; Kurahashi T; Fujisawa M
    Urol Oncol; 2013 Jul; 31(5):615-21. PubMed ID: 21600799
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels.
    Kurita Y; Suzuki A; Masuda H; Ushiyama T; Suzuki K; Fujita K
    Eur Urol; 1998; 33(1):32-8. PubMed ID: 9471039
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
    Ferro M; Crocetto F; La Civita E; Fiorenza M; Jannuzzi G; Carbone G; Sirica R; Sicignano E; Pagano G; Imbimbo C; Terracciano D
    Prostate; 2024 Sep; 84(12):1157-1164. PubMed ID: 38798011
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
    Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
    Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations.
    Veltri RW; Miller MC
    Urology; 1999 Apr; 53(4):736-45. PubMed ID: 10197849
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preoperative prostate health index predicts adverse pathology and Gleason score upgrading after radical prostatectomy for prostate cancer.
    Novak V; Vesely S; Luksanová H; Prusa R; Capoun O; Fiala V; Dolejsová O; Sedlacková H; Kucera R; Stejskal J; Zalesky M; Babjuk M
    BMC Urol; 2020 Sep; 20(1):144. PubMed ID: 32894109
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
    Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
    J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Naughton CK; Brawer MK; Flanigan RC; Richie JP; Patel A; Walsh PC; Scardino PT; Lange PH; deKernion JB; Southwick PC; Loveland KG; Parson RE; Gasior GH
    Urology; 2000 Mar; 55(3):372-6. PubMed ID: 10699613
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells.
    Zhang Y; Zippe CD; Van Lente F; Klein EA; Gupta MK
    Clin Cancer Res; 1997 Jul; 3(7):1215-20. PubMed ID: 9815802
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
    Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
    Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy.
    Cookson MS; Fleshner NE; Soloway SM; Fair WR
    Urology; 1997 Jun; 49(6):887-93. PubMed ID: 9187696
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
    Maeda H; Arai Y; Ishitoya S; Okubo K; Aoki Y; Okada T; Maekawa S
    Hinyokika Kiyo; 1998 May; 44(5):307-11. PubMed ID: 9656100
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Chun FK; Briganti A; Gallina A; Hutterer GC; Shariat SF; Antebie E; Walz J; Roehrborn CG; Salonia A; Rigatti P; Saad F; Huland H; Montorsi F; Graefen M; Karakiewicz PI
    Eur Urol; 2007 Oct; 52(4):1067-74. PubMed ID: 17383807
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Preoperative prostate specific antigen and prostate volume are significant predictors of seminal vesicle invasion in patients with prostate cancer.
    Sfoungaristos S; Perimenis P
    Prague Med Rep; 2011; 112(4):263-71. PubMed ID: 22142521
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
    Epstein JI; Walsh PC; Brendler CB
    J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
    Lucarelli G; Fanelli M; Larocca AM; Germinario CA; Rutigliano M; Vavallo A; Selvaggi FP; Bettocchi C; Battaglia M; Ditonno P
    Prostate; 2012 Nov; 72(15):1611-21. PubMed ID: 22430630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.